|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | +0.75% |
|
-1.47% | +8.06% |
| Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
| Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Akebia Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 194.62 million compared to USD 292.48 million a year ago. Net loss was USD 51.93 million compared to USD 94.23 million a year ago.
Basic loss per share from continuing operations was USD 0.28 compared to USD 0.52 a year ago. Diluted loss per share from continuing operations was USD 0.28 compared to USD 0.52 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 281M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
AKEBIA THERAPEUTICS, INC. 
